Bo Lu

Bo Lu

Auto-generated profile, based on publicly available information

Bo Lu

School of Chemistry, Department of Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan, 430070, China

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2018 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
LHLin Huang
Lin Huang
JLJia Liu
Jia Liu
FGFan Gao
Fan Gao
QCQian Cheng
Qian Cheng
BLBo Lu
Bo Lu
XZXuan Zeng
Xuan Zeng
In this study, a novel drug delivery system (HMSNs-SS-HA) based on hollow mesoporous silica nanoparticles (HMSNs) was developed for delivering anticancer drugs (e.g., doxorubicin (DOX)) to targeted tumour cells by using disulfide bonds as redox-sensitive linkers and hyaluronic acid (HA) molecules as both capping and targeting agents. Well-dispersed HMSNs were synthesized with a dimension of around 100 nm. Detailed physical characterization further demonstrated that HMSNs-SS-HA has been successfully constructed. The in vitro drug release experiments displayed the enzyme and redox dual-responsive and sustained drug release properties of DOX loaded HMSNs-SS-HA. Additionally, a series of biological evaluations indicated that these DOX loaded HMSNs-SS-HA could accurately target murine mammary carcinoma (4T1) cells to induce cell apoptosis in vitro and suppress tumour growth in vivo. These results demonstrated that DOX loaded HMSNs-SS-HA was suitable as a potential and efficient drug delivery nanosystem for cancer therapy.

1 November 2019 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
MSMei Shao
Mei Shao
CCCong Chang
Cong Chang
ZLZuhao Liu
Zuhao Liu
KCKai Chen
Kai Chen
YZYimin Zhou
Yimin Zhou
BLBo Lu
Bo Lu

1 October 2020 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
KCKai Chen
Kai Chen
CCCong Chang
Cong Chang
ZLZuhao Liu
Zuhao Liu
YZYimin Zhou
Yimin Zhou
QXQingni Xu
Qingni Xu
BLBo Lu
Bo Lu

14 February 2021 in Langmuir
Verified
Journal Article
Closed access
YZYimin Zhou
Yimin Zhou
CCCong Chang
Cong Chang
ZLZuhao Liu
Zuhao Liu
QZQiuling Zhao
Qiuling Zhao
QXQingni Xu
Qingni Xu
BLBo Lu
Bo Lu

31 December 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MYMengqi Yi
Mengqi Yi
BXBei Xiong
Bei Xiong
YLYuyang Li
Yuyang Li
WGWei Guo
Wei Guo
YHYunhan Huang
Yunhan Huang
BLBo Lu
Bo Lu

17 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
APAtanu Paul
Atanu Paul
SAStefano Annunziato
Stefano Annunziato
BLBo Lu
Bo Lu
TSTianliang Sun
Tianliang Sun
OEOlivera Evrova
Olivera Evrova
FCFeng Cong
Feng Cong
The Hippo/YAP pathway controls cell proliferation through sensing physical and spatial organization of cells. How cell-cell contact is sensed by Hippo signaling is poorly understood. Here, we identified the cell adhesion molecule KIRREL1 as an upstream positive regulator of the mammalian Hippo pathway. KIRREL1 physically interacts with SAV1 and recruits SAV1 to cell-cell contact sites. Consistent with the hypothesis that KIRREL1-mediated cell adhesion suppresses YAP activity, knockout of KIRREL1 increases YAP activity in neighboring cells. Analyzing pan-cancer CRISPR proliferation screen data reveals KIRREL1 as the top plasma membrane protein showing strong correlation with known Hippo regulators, highlighting a critical role of KIRREL1 in regulating Hippo signaling and cell proliferation. During liver regeneration in mice, KIRREL1 is upregulated, and its genetic ablation enhances hepatic YAP activity, hepatocyte reprogramming and biliary epithelial cell proliferation. Our data suggest that KIRREL1 functions as a feedback regulator of the mammalian Hippo pathway through sensing cell-cell interaction and recruiting SAV1 to cell-cell contact sites.